Allergan has paid $125 million for venture-backed Oculeve, a med-tech startup with a nerve-stimulating implant called OD-01 which is an...
Cassava Sciences, Inc. reported top-line results from a Phase IIb study of PTI 125, its lead investigational drug, in patients with Alzheimer’s disease. This study did not meet its primary endpoint. The pre-specified primary endpoint was a statistically significant effect of PTI 125 versus placebo on cerebrospinal fluid (CSF) levels of tau protein and other biomarker assessments from baseline to Day 28.
Celgene Corporation announced initial safety data from its ongoing proof-of-concept trial of JCARH 125 in patients with relapsed/refractory multiple myeloma...